Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.92 USD
Change Today 0.00 / 0.00%
Volume 65.4K
IMNP On Other Exchanges
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

immune pharmaceuticals inc (IMNP) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/29/14 - $4.25
52 Week Low
02/3/15 - $1.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

immune pharmaceuticals inc (IMNP) Related Bloomberg News

View More Bloomberg News

immune pharmaceuticals inc (IMNP) Related Businessweek News

No Related Businessweek News Found

immune pharmaceuticals inc (IMNP) Details

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes targeted therapeutics for the treatment of inflammatory diseases and cancer. The company’s lead product candidate is Bertilimumab, a human monoclonal antibody, which is under Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn's disease. It is also developing AmiKet, a prescription topical analgesic cream, which is in Phase III clinical trial to treat peripheral neuropathies; NanomAbs technology platform, an antibody-drug conjugate platform for the treatment of cancer; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is under Phase I/II clinical trials for the treatment of patients with solid tumors. The company has license, and other collaborative research and development arrangements with iCo Therapeutics Inc.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; MabLife SAS; Lonza Sales AG; Dalhousie University; Shire Biochem, Inc.; and Endo Pharmaceuticals. The company was founded in 2010 and is headquartered in New York, New York.

9 Employees
Last Reported Date: 04/15/15
Founded in 2010

immune pharmaceuticals inc (IMNP) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $342.5K
Compensation as of Fiscal Year 2014.

immune pharmaceuticals inc (IMNP) Key Developments

Immune Pharmaceuticals, Inc. Appoints BDO USA, LLP as Independent Registered Public Accounting Firm Replacing EisnerAmper LLP

On June 30, 2015, the Audit Committee of the Board of Directors of Immune Pharmaceuticals Inc. notified EisnerAmper LLP that it had determined not to engage Eisner as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2015, and accordingly dismissed Eisner effective as of such date. On and effective as of that same date, the company entered into an engagement letter with BDO USA, LLP, approved by the Audit Committee, and engaged BDO as the company’s independent registered public accounting firm.

Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid

Immune Pharmaceuticals, Inc. has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon selection. The bertilimumab Phase II Bullous Pemphigoid clinical trial is designed as an open label clinical trial in 10 patients, with moderate to severe Bullous Pemphigoid. Bullous Pemphigoid is an orphan chronic skin blistering disease affecting around 60,000 people globally, mostly in the elderly population, according to a Chardan Capital report. Primary end points include safety and efficacy, measured by a reduction in clinical symptoms and tapering down of systemic corticosteroids. Initial data is expected in late 2015 or early 2016. The bertilimumab Phase II Ulcerative Colitis clinical trial is designed as a double blind placebo controlled trial in 42 patients, with moderate to severe disease. Primary end points are safety and efficacy, measured by a reduction in the Mayo Clinic Ulcerative Colitis Disease Index at 8 weeks. Secondary end points include assessment of mucosal injury and clinical remission. Patients are selected based on Mayo score and high levels of tissue eotaxin-1 as well as other standardized clinical criteria. The completion of the clinical is expected by the end of 2016.

Immune Pharmaceuticals, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 02:10 PM

Immune Pharmaceuticals, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 02:10 PM. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Speakers: Daniel Gedeon Teper, Co-Founder, Chief Executive Officer and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMNP:US $1.92 USD 0.00

IMNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $2.26 USD -0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation IMNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNE PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at